Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Astrazeneca Pharma India Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹6,987.88Overvalued by 15.07%vs CMP ₹8,228.00

P/E (107.0) × ROE (23.3%) × BV (₹349.00) × DY (0.39%)

₹2,538.79Overvalued by 69.14%vs CMP ₹8,228.00
MoS: -224.1% (Negative)Confidence: 66/100 (Moderate)Models: 1 Fair, 9 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹8,851.6721%Fair (+7.6%)
Graham NumberEarnings₹794.3715%Over (-90.3%)
Earnings PowerEarnings₹358.3610%Over (-95.6%)
DCFCash Flow₹1,928.0610%Over (-76.6%)
Net Asset ValueAssets₹349.187%Over (-95.8%)
EV/EBITDAEnterprise₹1,366.738%Over (-83.4%)
Dividend DiscountDividends₹110.008%Over (-98.7%)
Earnings YieldEarnings₹803.607%Over (-90.2%)
ROCE CapitalReturns₹892.128%Over (-89.2%)
Revenue MultipleRevenue₹1,029.555%Over (-87.5%)
Consensus (10 models)₹2,538.79100%Overvalued
Key Drivers: EPS CAGR 26.7% lifts DCF — verify sustainability. | P/E of 107 makes PE-ROE unreliable — asset/earnings models are better benchmarks.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 26.7%

*Investments are subject to market risks

Analyst Summary

Astrazeneca Pharma India Ltd operates in the Pharmaceuticals segment, NSE: ASTRAZEN | BSE: 506820, current market price is ₹8,228.00, market cap is 20,571 Cr.. At a glance, stock P/E is 107, ROE is 23.3 %, ROCE is 29.3 %, book value is 349, dividend yield is 0.39 %. The latest intrinsic value estimate is ₹2,538.79, around 69.1% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹1,716 Cr versus the prior period change of 32.4%, while latest net profit is about ₹116 Cr with a prior-period change of -28.4%. The 52-week range shown on this page is 10,691/7,552, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisAstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CI…

This summary is generated from the stock page data available for Astrazeneca Pharma India Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

74
Astrazeneca Pharma India Ltd scores 74/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health92/100 · Strong
ROCE 29.3% ExcellentROE 23.3% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money65/100 · Strong
FII holding stable No changeDII holding up 0.90% MF buyingPromoter holding at 75.0% Stable
Earnings Quality50/100 · Moderate
OPM stable around 15% Steady
Quarterly Momentum90/100 · Strong
Revenue (4Q): +35% YoY AcceleratingProfit (4Q): +146% YoY Strong
Industry Rank60/100 · Moderate
P/E 107.0 vs industry 49.9 Premium to peersROCE 29.3% vs industry 24.9% AverageROE 23.3% vs industry 18.3% Above peers3Y sales CAGR: 29% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: June 12, 2026, 4:29 am

Market Cap 20,571 Cr.
Current Price 8,228
Intrinsic Value₹2,538.79
High / Low 10,691/7,552
Stock P/E107
Book Value 349
Dividend Yield0.39 %
ROCE29.3 %
ROE23.3 %
Face Value 2.00
PEG Ratio4.01

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Astrazeneca Pharma India Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Astrazeneca Pharma India Ltd 20,571 Cr. 8,228 10,691/7,552107 3490.39 %29.3 %23.3 % 2.00
Pfizer Ltd 20,920 Cr. 4,573 5,993/4,39727.6 9191.64 %24.2 %18.0 % 10.0
Neuland Laboratories Ltd 21,776 Cr. 16,973 19,748/11,50059.8 1,4610.20 %26.6 %21.4 % 10.0
ERIS Lifesciences Ltd 18,923 Cr. 1,366 1,904/1,20029.9 2820.54 %14.1 %18.7 % 1.00
Granules India Ltd 18,911 Cr. 763 804/43331.4 2050.23 %15.5 %13.7 % 1.00
Industry Average21,214.12 Cr1,194.5949.88218.190.36%24.92%18.30%6.10

All Competitor Stocks of Astrazeneca Pharma India Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 236250285295311306383388408440480526559
Expenses 195213225228258291334349355363394445484
Operating Profit 41376067531549385377868175
OPM % 17%15%21%23%17%5%13%10%13%17%18%15%13%
Other Income 77-32825109-498-2610111
Interest 000001-0000111
Depreciation 344444449918173
Profit before tax 44392371732054-155142787573
Tax % 26%26%26%25%29%23%27%-22%25%27%26%25%26%
Net Profit 33291754521639-123831585654
EPS in Rs 13.0211.726.9121.5420.956.3215.79-4.7215.3712.3423.3022.3321.69

Last Updated: January 2, 2026, 9:31 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 23, 2026, 10:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 4745175645445717288328148061,0031,2961,7162,177
Expenses 4875285475065256577116787198381,1111,4621,890
Operating Profit -13-111637467112113586165184254287
OPM % -3%-2%3%7%8%10%15%17%11%16%14%15%13%
Other Income 2367141216131315-1451-5629
Interest 0000001111113
Depreciation 10151716151519201716154041
Profit before tax 0-21636447311412783134220156273
Tax % 0%9%44%41%25%37%27%26%26%26%26%
Net Profit -1-21520265472936299162116201
EPS in Rs -0.20-8.342.108.0210.3621.7828.8837.3224.6439.7264.6046.3080.36
Dividend Payout % 0%0%0%0%0%0%3%5%41%40%37%69%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-2000.00%123.81%300.00%30.00%107.69%33.33%29.17%-33.33%59.68%63.64%-28.40%
Change in YoY Net Profit Growth (%)0.00%2123.81%176.19%-270.00%77.69%-74.36%-4.17%-62.50%93.01%3.96%-92.03%

Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:16%
3 Years:29%
TTM:34%
Compounded Profit Growth
10 Years:26%
5 Years:19%
3 Years:43%
TTM:61%
Stock Price CAGR
10 Years:23%
5 Years:19%
3 Years:44%
1 Year:32%
Return on Equity
10 Years:19%
5 Years:21%
3 Years:23%
Last Year:24%

Last Updated: September 4, 2025, 11:55 pm

Balance Sheet

Last Updated: June 17, 2026, 5:00 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 555555555555
Reserves 146151218242296359451506584707765868
Borrowings 00000121297536111
Other Liabilities 2612471932142613303063373893627121,006
Total Liabilities 4124034154615627067758579851,0781,5181,989
Fixed Assets 10197877575728174696764117
CWIP 12654724421000
Investments 000000000000
Other Assets 2982993243824806116907809151,0111,4541,872
Total Assets 4124034154615627067758579851,0781,5181,989

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + -46573895587105101582865-15
Cash from Investing Activity + -19-40-94-171173518223119
Cash from Financing Activity + 0-1000-6-9-9-24-44-66-92
Net Cash Flow -645338-159-902699652531-88
Free Cash Flow -694833337749994531864-18
CFO/OP 393%365%133%28%126%100%101%146%60%46%51%26%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-13.00-11.0016.0037.0046.0071.00109.00123.0077.00158.00179.00218.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 413054293540373839394339
Inventory Days 210157141121229186197198164193140208
Days Payable 241203174184257266251221223231121173
Cash Conversion Cycle 10-1621-347-39-1715-2016274
Working Capital Days -45-15-28-36-8-14-16-17-34-182022
ROCE %-12%-13%4%15%19%27%34%30%16%31%31%33%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs 2.70%2.68%2.69%2.66%2.73%2.79%2.90%2.92%2.89%3.03%2.74%2.71%
DIIs 1.41%1.91%2.42%2.76%3.77%4.99%5.08%5.21%4.65%4.55%5.26%5.55%
Public 20.88%20.40%19.89%19.57%18.50%17.21%17.02%16.85%17.45%17.41%17.00%16.73%
No. of Shareholders 42,14638,94632,38029,03229,41827,16927,61527,32232,46634,37832,91431,551

Shareholding Pattern Chart

No. of Shareholders

Astrazeneca Pharma India Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund 659,875 0.86 564.19658,0752026-02-22 10:32:570.27%
Bandhan Large & Mid Cap Fund 127,498 0.78 109.01110,6372026-02-23 05:56:3115.24%
Bandhan Innovation Fund 85,237 3.81 72.8883,9642026-02-22 00:09:031.52%
Nippon India Pharma Fund 62,568 0.68 53.511,5612025-12-08 04:19:42441.2%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 58,282 0.75 49.8355,0212026-02-22 10:32:575.93%
Baroda BNP Paribas Small Cap Fund 32,200 2.36 27.53N/AN/AN/A
Baroda BNP Paribas Manufacturing Fund 27,900 2.65 23.8530,6002026-02-23 08:14:38-8.82%
ICICI Prudential Multicap Fund 27,260 0.15 23.3122,0902026-02-22 10:32:5723.4%
ICICI Prudential Smallcap Fund 21,370 0.22 18.2718,8702026-02-22 10:32:5713.25%
Bandhan Aggressive Hybrid Fund 21,217 1.11 18.1420,0442026-02-23 02:46:195.85%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 46.3064.6039.7024.6037.30
Diluted EPS (Rs.) 46.3064.6039.7024.6037.30
Cash EPS (Rs.) 62.2970.5846.2231.4245.37
Book Value[Excl.RevalReserv]/Share (Rs.) 308.14284.77235.48204.56182.47
Book Value[Incl.RevalReserv]/Share (Rs.) 308.14284.77235.48204.56182.47
Dividend / Share (Rs.) 32.0024.0016.0010.002.00
Revenue From Operations / Share (Rs.) 686.52518.21401.19322.24325.42
PBDIT / Share (Rs.) 117.8487.7076.4940.3859.32
PBIT / Share (Rs.) 101.8481.7269.9833.6051.27
PBT / Share (Rs.) 62.5487.8253.6433.2250.84
Net Profit / Share (Rs.) 46.3064.6039.7224.6437.32
PBDIT Margin (%) 17.1616.9219.0612.5218.22
PBIT Margin (%) 14.8315.7717.4410.4215.75
PBT Margin (%) 9.1116.9413.3710.3015.62
Net Profit Margin (%) 6.7412.469.897.6411.46
Return on Networth / Equity (%) 15.0222.6816.8612.0420.45
Return on Capital Employeed (%) 31.2328.3429.1116.0327.20
Return On Assets (%) 7.6214.9810.087.1912.04
Asset Turnover Ratio (%) 1.321.261.090.981.10
Current Ratio (X) 1.912.612.182.122.04
Quick Ratio (X) 1.131.971.681.701.51
Inventory Turnover Ratio (X) 4.420.610.510.590.59
Dividend Payout Ratio (NP) (%) 51.8424.7620.148.115.35
Dividend Payout Ratio (CP) (%) 38.5222.6617.306.364.40
Earning Retention Ratio (%) 48.1675.2479.8691.8994.65
Cash Earning Retention Ratio (%) 61.4877.3482.7093.6495.60
Interest Coverage Ratio (X) 201.78182.71303.52106.25136.06
Interest Coverage Ratio (Post Tax) (X) 146.57121.90222.4665.8486.60
Enterprise Value (Cr.) 20979.1812795.167617.775940.177173.15
EV / Net Operating Revenue (X) 12.229.887.607.378.82
EV / EBITDA (X) 71.2158.3639.8458.8548.37
MarketCap / Net Operating Revenue (X) 12.5410.278.097.939.25
Retention Ratios (%) 48.1575.2379.8591.8894.64
Price / BV (X) 27.9318.6813.7912.4916.50
Price / Net Operating Revenue (X) 12.5410.278.097.939.25
EarningsYield 0.010.010.010.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 2275.58 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2026.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBlock N1, 12th Floor, Bengaluru Karnataka 560045Contact not found
Management
NamePosition Held
Ms. Shilpa Divekar NirulaChairperson & Independent Director
Mr. Praveen Rao AkkinepallyManaging Director
Ms. Bhavana AgrawalExecutive Director
Ms. Sylvia Lorena Varela RamonNon Executive Director
Ms. Hooi Bien ChuahNon Executive Director
Mr. Jesus Javier Diaz-Ropero EstesoNon Executive Director
Ms. Revathy AshokIndependent Director
Ms. Monica WidhaniIndependent Director

FAQ

What is the intrinsic value of Astrazeneca Pharma India Ltd and is it undervalued?

As of 19 June 2026, Astrazeneca Pharma India Ltd's intrinsic value is ₹2538.79, which is 69.14% lower than the current market price of ₹8,228.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (23.3 %), book value (₹349), dividend yield (0.39 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Astrazeneca Pharma India Ltd?

Astrazeneca Pharma India Ltd is trading at ₹8,228.00 as of 19 June 2026, with a FY2026-2027 high of ₹10,691 and low of ₹7,552. The stock is currently near its 52-week low. Market cap stands at ₹20,571 Cr..

How does Astrazeneca Pharma India Ltd's P/E ratio compare to its industry?

Astrazeneca Pharma India Ltd has a P/E ratio of 107, which is above the industry average of 49.88. This significantly elevated P/E suggests the market expects strong future growth, or the stock may be overpriced relative to current earnings.

Is Astrazeneca Pharma India Ltd financially healthy?

Key indicators for Astrazeneca Pharma India Ltd: ROCE of 29.3 % indicates efficient capital utilization; ROE of 23.3 % shows strong shareholder returns. Dividend yield is 0.39 %.

Is Astrazeneca Pharma India Ltd profitable and how is the profit trend?

Astrazeneca Pharma India Ltd reported a net profit of ₹116 Cr in Mar 2025 on revenue of ₹1,716 Cr. Compared to ₹62 Cr in Mar 2022, the net profit shows an improving trend.

Does Astrazeneca Pharma India Ltd pay dividends?

Astrazeneca Pharma India Ltd has a dividend yield of 0.39 % at the current price of ₹8,228.00. The company pays dividends, though the yield is modest.

Last Updated: June 12, 2026, 4:29 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 506820 | NSE: ASTRAZEN
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Astrazeneca Pharma India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports